CYTK Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
47.6M
+66.1%
28.6M
+47.9%
19.4M
+9.0%
17.8M
+817.1%
1.9M
Cost of Revenue
-454000
-116.6%
2.7M
+7.0%
2.6M
0
0
Gross Profit
48.0M
+85.4%
25.9M
+54.1%
16.8M
-5.4%
17.8M
+817.1%
1.9M
Operating Expenses
215.1M
+4.9%
205.1M
+2.3%
200.4M
+2.2%
196.1M
+16.3%
168.7M
R&D
99.3M
+1.5%
97.8M
+2.4%
95.5M
-8.5%
104.4M
+7.3%
97.3M
SG&A
113.1M
+8.4%
104.4M
-0.5%
104.9M
+14.4%
91.7M
+32.1%
69.5M
Operating Income
-167088000
+6.7%
-179172000
+2.4%
-183618000
-2.9%
-178366000
-7.0%
-166755000
EBITDA
-163440000
+6.9%
-175541000
+2.6%
-180240000
-2.7%
-175505000
-7.0%
-164076000
Net Income
-190069000
+4.4%
-198762000
+3.5%
-206031000
-233.5%
-61782000
+66.6%
-184929000
EPS (Basic)
$-1.37
+8.7%
$-1.50
+10.2%
$-1.67
-12.1%
$-1.49
+41.6%
$-2.55
EPS (Diluted)
$-1.37
+8.7%
$-1.50
+10.2%
$-1.67
-12.1%
$-1.49
+41.6%
$-2.55
Shares (Diluted)
139.0M
+5.3%
132.1M
+7.1%
123.3M
+0.6%
122.5M
+2.1%
120.0M
Cytokinetics (CYTK) — Financials